Search

Your search keyword '"Dalgard O"' showing total 337 results

Search Constraints

Start Over You searched for: Author "Dalgard O" Remove constraint Author: "Dalgard O"
337 results on '"Dalgard O"'

Search Results

1. Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions

2. Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions

6. The present and future disease burden of hepatitis C virus (HCV) infections with todayʼs treatment paradigm – volume 2

7. Strategies to manage hepatitis C virus (HCV) infection disease burden – volume 2

8. Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 2

31. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study

33. A172 C-EDGE CO-STAR: RISK OF REINFECTION FOLLOWING SUCCESSFUL THERAPY WITH ELBASVIR (EBR) AND GRAZOPREVIR (GZR) IN PERSONS WHO INJECT DRUGS (PWID) RECEIVING OPIOD AGONIST THERAPY (OAT)

34. O13 Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study

35. O21 HCV reinfection and injecting risk behaviour following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR three year follow-up study

36. Restrictions for reimbursement of interferon-free direct-acting antiviral therapies for HCV infection in Europe

38. Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study

39. The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2

40. Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2

41. Strategies to manage hepatitis C virus (HCV) infection disease burden - volume 2

42. Hepatitis C Virus Core Antigen: A Simplified Treatment Monitoring Tool, including for Post-Treatment Relapse

43. The Effect of Sofosbuvir Containing Regimes in Patients with HCV Genotype 3 Infection-A Scandinavian Real-Life Experience

44. C-Edge Co-Star: Risk of Reinfection following Successful Therapy with Elbasvir and Grazoprevir in Persons who Inject Drugs (PWID) Receiving Opioid Agonist Therapy (OAT)

45. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel

47. P0842 : Malachite-I: Phase 3B Trial of ombitasvir/paritaprevir/r and dasabuvir +/− ribavirin or telaprevir + peginterferon/ribavirin in treatment-naïve adults with HCV genotype 1

48. P0848 : Efficacy of response-guided pegylated interferon and ribavirin therapy for people who inject drugs with HCV genotype 2/3 infection: The activate study

49. Piloting mental health indicators for Europe

50. P1214 RIBAVIRIN MONOTHERAPY REDUCES HCVRNA IN ASSOCIATION WITH IL28B GENOTYPE AND ALSO IP-10 CONCENTRATIONS AMONG PATIENTS INFECTED WITH HEPATITIS C GENOTYPE 1

Catalog

Books, media, physical & digital resources